Proliferatory defect of invariant population and accumulation of non-invariant CD1d-restricted natural killer T cells in the joints of RA patients

Modern Rheumatology

Volumn 24, Issue 3, 2014, Pages 434-442

  Gutowska Owsiak, Danuta ^a   Birchall, Martin A ^b   Moots, Robert J ^a   Christmas, Stephen E ^a   Pazmany, Laszlo ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Autoimmunity; CD1d; NKT cells; Rheumatoid arthritis; GalCer

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CD1D ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; CD4 ANTIGEN; CYTOKINE;

ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEASIBILITY STUDY; HUMAN; HUMAN CELL; INVARIANT NATURAL KILLER T CELL; LYMPHOCYTE PROLIFERATION; MONONUCLEAR CELL; NATURAL KILLER T CELL; NON INVARIANT NATURAL KILLER T CELL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; TH2 CELL; CELL PROLIFERATION; IMMUNOLOGY; JOINT; METABOLISM; PATHOLOGY;

ANTIGENS, CD4; ARTHRITIS, RHEUMATOID; CELL PROLIFERATION; CYTOKINES; HUMANS; JOINTS; NATURAL KILLER T-CELLS; SYNOVIAL FLUID;

EID: 84900387095     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2013.844309     Document Type: Article

References (51)

1. Baxter AG. Kinder SJ. Hammond KJ. Scollay R. Godfrey DI. Association between alphabetaTCR- CD4-CD8-T-cell defi ciency and IDDM in NOD/Lt mice. Diabetes. 1997; 46(4): 572-82
2. Godfrey D I Kinder S J Silvera P. Baxter A G. Flow cytometric study of T cell development in NOD mice reveals a defi ciency in alphabeta TCR- CDR-CD8-Thymocytes. J. Autoimmun. 1997; 10(3): 279-85
3. Takeda K. Hayakawa Y. Van Kaer L. Matsuda H. Yagita H Okumura K. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Natl Acad Sci U S A. 2000; 97(10): 5498-503
4. Gombert J M Herbelin A. Tancrede-Bohin E. D y M. Carnaud C Bach JF. Early quantitative and functional defi ciency of NK1- -like thymocytes in the NOD mouse. Eur J Immunol. 1996; 26(12) : 2989-98
5. Matsuki N. Stanic AK. Embers ME. Van Kaer L. Morel L. Joyce S. Genetic dissection of V alpha 14J alpha 18 natural T cell number and function in autoimmune-prone mice. J. Immunol. 2003 ; 170(11): 5429-37
6. Yang J Q Wen X. Liu H. Folayan G. Dong X. Zhou M. e t a l. Examining the role of CD1d and natural killer T cells in the development of nephritis in a genetically susceptible lupus model. Arthritis Rheum. 2007; 56(4): 1219-33
7. Araki M. Kondo T. Gumperz J E Brenner M B Miyake S Yamamura T. Th2 bias of CD4- NKT cells derived from multiple sclerosis in remission. Int Immunol. 2003; 15(2): 279-88
8. van Der Vliet HJ. von Blomberg BM. Nishi N. Reijm M. Voskuyl AE van Bodegraven AA et al. Circulating V(alpha24- ) Vbeta11- NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin Immunol. 2001; 100(2): 144-8
9. Wilson SB. Kent SC. Patton KT. Orban T. Jackson RA. Exley M et al. Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes. Nature. 1998; 391(6663): 177-81
10. Oikawa Y. Shimada A. Yamada S. Motohashi Y. Nakagava Y. Irie J et al. High frequency of valpha24(- ) vbeta11(- ) T-cells observed in type 1 diabetes. Diabetes Care. 2002; 25(10): 1818-23
11. L ee P T Putnam A. Benlagha K. Teyton L. Gottlieb P A Bendelac A. Testing the NKT cell hypothesis of human IDDM pathogenesis. J. Clin Invest. 2002; 110(6): 793-800
12. Lantz O. Bendelac A. A n invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specifi c CD4- and CD4-8-T cells in mice and humans. J. Exp Med. 1994; 180(3): 1097-106
13. Porcelli S. Yockey C E Brenner M B Balk S P. Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4-8-Alpha/beta T cells demonstrates preferential use of several V beta genes and an invariant TCR alpha chain. J. Exp Med. 1993; 178(1) : 1-16
14. Arase H. Arase N. Ogasawara K. Good R A Onoe K. A n NK1.1- CD4- 8-single-positive thymocyte subpopulation that expresses a highly skewed T-cell antigen receptor V beta family. Proc Natl Acad Sci U S A. 1992; 89(14): 6506-10
15. Porcelli S. Gerdes D. Fertig A M Balk S P. Human T cells expressing an invariant V alpha 24-J alpha Q TCR alpha are CD4-And heterogeneous with respect to TCR beta expression. Hum Immunol. 1996; 48(1-2): 63-7
16. Kojo S. Adachi Y. Keino H. Taniguchi M. Sumida T. Dysfunction of T cell receptor AV24AJ18-. BV11- double-negative regulatory natural killer T cells in autoimmune diseases. Arthritis Rheum. 2001; 44(5): 1127-38
17. Linsen L. Thewissen M. Baeten K. Somers V. Geusens P. Raus J Stinissen P. Peripheral blood but not synovial fl uid natural killer T cells are biased towards a Th1-like phenotype in rheumatoid arthritis. Arthritis Res Ther. 2005; 7(3): R493-502
18. Maeda T. Keino H. Asahara H. Taniguchi M. Nishioka K. Sumida T. Decreased TCR AV24AJ18- double-negative T cells in rheumatoid synovium. Rheumatology (Oxford). 1999; 38(2): 186-8
19. Lin H. Nieda M. Nicol AJ. Diff erential proliferative response of NKT cell subpopulations to in vitro stimulation in presence of diff erent cytokines. Eur J Immunol. 2004; 34(10): 2664-71
20. Gadola SD. Dulphy N. Salio M. Cerundolo V. Valpha24-JalphaQindependent CD1d-restricted recognition of alpha-galactosylceramide by human CD4(- ) and CD8alphabeta(- ) T lymphocytes. J. Immunol. 2002; 168(11): 5514-20
21. Gumperz J E Miyake S. Yamamura T. Brenner M B. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J. Exp Med. 2002; 195(5): 625-36
22. Renukaradhya G J Khan M A Vieira M. D u W. Gervay-Hague J Brutkiewicz RR. Type I NKT cells protect (and type II NKT cells suppress) the host s innate antitumor immune response to a B-cell lymphoma. Blood. 2008; 111(12): 5637-45
23. Halder R C Aguilera C. Maricic I. Kumar V. Type II NKT cellmediated anergy induction in type I NKT cells prevents infl ammatory liver disease. J. Clin Invest. 2007; 117(8): 2302-12
24. Thedrez A. d e Lalla C. Allain S. Zaccagnino L. Sidobre S Garavaglia C et al. CD4 engagement by CD1d potentiates activation of CD4- invariant NKT cells. Blood. 2007
25. L ee P T Benlagha K. Teyton L. Bendelac A. Distinct functional lineages of human V(alpha)24 natural killer T cells. J. Exp Med. 2002; 195(5): 637-41
26. Kim CH. Butcher EC. Johnston B. Distinct subsets of human Valpha24-invariant NKT cells: Cytokine responses and chemokine receptor expression. Trends Immunol. 2002; 23(11): 516-9
27. Stetson DB. Mohrs M. Reinhardt RL. Baron JL. Wang ZE. Gapin L et al. Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised for rapid eff ector function. J. Exp Med. 2003 ; 198(7): 1069-76
28. Takahashi T. Chiba S. Nieda M. Azuma T. Ishihara S. Shibata Y et al. Cutting edge: Nalysis of human V alpha 24- CD8- NK T cells activated by alpha-galactosylceramide-pulsed monocyte-derived dendritic cells. J. Immunol. 2002; 168(7): 3140-4
29. Mendiratta S K Martin W D Hong S. Boesteanu A. Joyce S Van Kaer L. CD1d1 mutant mice are defi cient in natural T cells that promptly produce IL-4. Immunity. 1997; 6(4): 469-77
30. Exley M. Garcia J. Balk S P Porcelli S. Requirements for CD1d recognition by human invariant Valpha24- CD4-CD8-T cells. J. Exp Med. 1997; 186(1): 109-20
31. Arase H. Arase N. Nakagawa K. Good R A Onoe K. N K1.1- CD4- CD8-Thymocytes with specifi c lymphokine secretion. Eur J Immunol. 1993; 23(1): 307-10
32. Yoshimoto T. Paul W E. C D4pos NK1.1pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. J Exp Med. 1994; 179(4): 1285-95
33. C ui J. Shin T. Kawano T. Sato H. Kondo E. Toura I. e t a l. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science. 1997; 278(5343): 1623-6
34. Mattner J. Debord K L Ismail N. Goff RD. Cantu C III. Zhou D. et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature. 2005; 434(7032): 525-9
35. Beaudoin L. Laloux V. Novak J. Lucas B. Lehuen A. N KT cells inhibit the onset of diabetes by impairing the development of pathogenic T cells specifi c for pancreatic beta cells. Immunity. 2002; 17(6): 725-36
36. Hong S. Wilson MT. Serizawa I. Wu L. Singh N. Naidenko OV et al. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med. 2001; 7(9): 1052-6
37. Sharif S. Arreaza GA. Zucker P. Mi QS. Sondhi J. Naidenko OV et al. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat Med. 2001; 7(9): 1057-62
38. Gumperz J E Roy C. Makowska A. Lum D. Sugita M. Podrebarac T et al. Murine CD1d-restricted T cell recognition of cellular lipids. Immunity. 2000; 12(2): 211-21
39. Pridgeon C. Lennon GP. Pazmany L. Thompson RN. Christmas SE Moots RJ. Natural killer cells in the synovial fl uid of rheumatoid arthritis patients exhibit a CD56brightCD94brightCD158negative phenotype. Rheumatology (Oxford). 2003; 42(7): 870-8
40. Chiba A. Oki S. Miyamoto K. Hashimoto H. Yamamura T Miyake S. Suppression of collagen-induced arthritis by natural killer T cell activation with OCH asphingosine-Truncated analog of alpha-galactosylceramide. Arthritis Rheum. 2004; 50(1): 305-13
41. O ki S. Chiba A. Yamamura T. Miyake S. The clinical implication and molecular mechanism of preferential IL-4 production by modifi ed glycolipid-stimulated NKT cells. JClin Invest. 2004;113(11): 1631-40
42. L ee A. Farrand K J Dickgreber N. Hayman C M J ü r s S. Hermans I F et al. Novel synthesis of alpha-galactosyl-ceramides and confi rmation of their powerful NKT cell agonist activity. Carbohydr Res. 2006; 341(17): 2785-98
43. Zhang L. Yuan S. Cheng G. Guo B. Type I IFN promotes IL-10 production from T cells to suppress Th17 cells and Th17-Associated autoimmune infl ammation. PLoS One. 2011; 6(12): E28432
44. Yang M. Deng J. Liu Y. Ko KH. Wang X. Jiao Z. et al. IL-10-producing regulatory B10 cells ameliorate collagen-induced arthritis via suppressing Th17 cell generation. Am J Pathol. 2012 ; 180(6): 2375-85
45. L iu B. Tonkonogy S L Sartor R B. Antigen-presenting cell production of IL-10 inhibits T-helper 1 and 17 cell responses and suppresses colitis in mice. Gastroenterology. 2011; 141(2): 653-62
46. L iu Y. Teige A. Mondoc E. Ibrahim S. Holmdahl R. Issazadeh-Navikas S. Endogenous collagen peptide activation of CD1d-restricted NKT cells ameliorates tissue-specifi c infl ammation in mice. J. Clin Invest. 2011; 121(1): 249-64
47. Jung S. Park YK. Shin JH. Lee H. Kim SY. Lee GR. Park SH. The requirement of natural killer T-cells in tolerogenic APCsmediated suppression of collagen-induced arthritis. Exp Mol Med. 2010; 42(8): 547-54
48. Teige A. Bockermann R. Hasan M. Olofsson K E Liu Y Issazadeh-Navikas S. CD1d-dependent NKT cells play a protective role in acute and chronic arthritis models by ameliorating antigenspecifi c Th1 responses. J. Immunol. 2010; 185(1): 345-56
49. Horikoshi M. Goto D. Segawa S. Yoshiga Y. Iwanami K. Inoue A et al. Activation of Invariant NKT cells with glycolipid ligand ?.?.-galactosylceramide ameliorates glucose-6-phosphate isomerase peptide-induced arthritis. PLoS One. 2012; 7(12): E51215
50. Hu M. Bassett JH. Danks L. Howell PG. Xu K. Spanoudakis E. et al. Activated invariant NKT cells regulate osteoclast development and function. J. Immunol. 2011; 186(5): 2910-7
51. Park Y. Kim HS. Ahn JY. Yun D. Cho ML. Hong S. et al. IL-12p35 promotes antibody-induced joint infl ammation by activating NKT cells and suppressing TGF-beta. J. Immunol. 2010; 185(3): 1476-84